{
    "organizations": [],
    "uuid": "d3a8b2e2b4135cbbcecbf89bc21904cde275c961",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-retrophin-expects-total-net-produc/brief-retrophin-expects-total-net-product-sales-of-approximately-155-million-in-2018-idUSASB0C01J",
    "ord_in_thread": 0,
    "title": "BRIEF-Retrophin Expects Total Net Product Sales Of Approximately $155 Million​ In 2018",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "Jan 8 (Reuters) - Retrophin Inc:\n* RETROPHIN PROVIDES CORPORATE UPDATE AND 2018 OUTLOOK * ‍FOR FISCAL YEAR 2017, COMPANY EXPECTS TOTAL NET PRODUCT SALES OF APPROXIMATELY $155 MILLION​\n* ‍COMPANY EXPECTS NET PRODUCT SALES FOR Q4 OF 2017 TO BE APPROXIMATELY $42 MILLION​\n* ‍COMPANY EXPECTS A NEW DRUG APPLICATION FILING IN 2018 FOR ITS NEW FORMULATION OF THIOLA FOR TREATMENT OF CYSTINURIA Source text for Eikon: Further company coverage:\n ",
    "published": "2018-01-08T20:10:00.000+02:00",
    "crawled": "2018-01-09T16:52:11.000+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "jan",
        "reuters",
        "retrophin",
        "inc",
        "retrophin",
        "provides",
        "corporate",
        "update",
        "outlook",
        "fiscal",
        "year",
        "company",
        "expects",
        "total",
        "net",
        "product",
        "sale",
        "approximately",
        "expects",
        "net",
        "product",
        "sale",
        "q4",
        "approximately",
        "expects",
        "new",
        "drug",
        "application",
        "filing",
        "new",
        "formulation",
        "thiola",
        "treatment",
        "cystinuria",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}